Mixing Business And Philanthropy Yields Returns For Glaxo In Africa
GlaxoSmithKline is having success with its "hybrid" approach in Africa, combining no-nonsense business with the aim of improving access to medicines there – in part through deeply discounted prices, measuring managers’ sales performances by the amount of drugs sold, rather than profits, and reinvesting in health infrastructure.
You may also be interested in...
VentureHealth combines the best in venture and crowdfunding, and has two exits to show for it. Plus Valeant buys Bausch & Lomb, GSK buys Okairos, AZ buys Omthera, while ThromboGenics/Array, Pfizer/UCSF, and Amgen/Astellas do deals.
The British pharma has done the biggest takeout of a private, clinical-stage European biotech so far this year. It is focused on a Phase I RSV vaccine and a T-cell stimulating technology. As for VCs, they have nabbed roughly a 10x return on their invested capital.
VCs address the need for new capital at the U.K’s BioTrinity partnering and investor meeting; France and Germany move to work together on translational drug research; and France’s suspension of Bayer’s Diane 35 shows its tougher regulatory line.